Do analysts rate BCYC or BOLD?

Bicycle Therapeutics currently has a consensus target price of $13.86, indicating a potential upside of 284.92%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AKBA or BOLD?

Akebia Therapeutics presently has a consensus price target of $3.90, indicating a potential upside of 318.19%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BOLD or CUE?

Cue Biopharma has a consensus price target of $83.00, suggesting a potential upside of 161.75%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cue Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer BOLD or FHTX?

Foghorn Therapeutics has a consensus price target of $11.67, indicating a potential upside of 201.46%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts rate ALXO or BOLD?

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 212.93%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ALXO or BOLD?

ALX Oncology is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.13 N/A Boundless Bio N/A N/A -$58.20M -$2.86 N/A

Is ALXO or BOLD more profitable?

Boundless Bio's return on equity of -70.89% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% Boundless Bio N/A -70.89% -47.37%

Boundless Bio (BOLD) Competitors

$2.70 -0.18 (-6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$2.72 +0.01 (+0.56%)

As of 07:30 PM Eastern

Compare

BOLD vs. BCYC, AKBA, CUE, FHTX, and ALXO

Should you buy Boundless Bio stock or one of its competitors? Boundless Bio's main competitors and comparable companies include Bicycle Therapeutics (BCYC), Akebia Therapeutics (AKBA), Cue Biopharma (CUE), Foghorn Therapeutics (FHTX), and ALX Oncology (ALXO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Boundless Bio compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Boundless Bio has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$61.21M	4.12	-$218.96M	-$2.73	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

Boundless Bio has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Boundless Bio	N/A	-70.89%	-47.37%

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Bicycle Therapeutics had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for Bicycle Therapeutics and 0 mentions for Boundless Bio. Bicycle Therapeutics' average media sentiment score of 0.00 equaled Boundless Bio'saverage media sentiment score.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
Boundless Bio	Neutral

Bicycle Therapeutics currently has a consensus target price of $13.86, indicating a potential upside of 284.92%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bicycle Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Summary

Bicycle Therapeutics beats Boundless Bio on 10 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Akebia Therapeutics presently has a consensus price target of $3.90, indicating a potential upside of 318.19%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Akebia Therapeutics has higher revenue and earnings than Boundless Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.09	-$5.34M	-$0.11	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

Boundless Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Boundless Bio's return on equity of -70.89% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Boundless Bio	N/A	-70.89%	-47.37%

Akebia Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 23.1% of Boundless Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Akebia Therapeutics had 3 more articles in the media than Boundless Bio. MarketBeat recorded 3 mentions for Akebia Therapeutics and 0 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 0.00 beat Akebia Therapeutics' score of -0.02 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Akebia Therapeutics	Neutral
Boundless Bio	Neutral

Summary

Akebia Therapeutics beats Boundless Bio on 10 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to Cue Biopharma?

Boundless Bio (NASDAQ:BOLD) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

35.0% of Cue Biopharma shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Boundless Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Boundless Bio's return on equity of -70.89% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Cue Biopharma	-435.83%	-620.06%	-291.15%

In the previous week, Cue Biopharma had 17 more articles in the media than Boundless Bio. MarketBeat recorded 17 mentions for Cue Biopharma and 0 mentions for Boundless Bio. Cue Biopharma's average media sentiment score of 0.60 beat Boundless Bio's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Boundless Bio	Neutral
Cue Biopharma	Positive

Boundless Bio has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market.

Cue Biopharma has higher revenue and earnings than Boundless Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Cue Biopharma	$27.47M	8.38	-$26.60M	-$27.02	N/A

Cue Biopharma has a consensus price target of $83.00, suggesting a potential upside of 161.75%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cue Biopharma beats Boundless Bio on 9 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to Foghorn Therapeutics?

Boundless Bio (NASDAQ:BOLD) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Boundless Bio's average media sentiment score of 0.00 equaled Foghorn Therapeutics'average media sentiment score.

Company	Overall Sentiment
Boundless Bio	Neutral
Foghorn Therapeutics	Neutral

61.6% of Foghorn Therapeutics shares are held by institutional investors. 23.1% of Boundless Bio shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Boundless Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market.

Boundless Bio has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Foghorn Therapeutics	$30.91M	7.43	-$74.28M	-$0.98	N/A

Boundless Bio has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Foghorn Therapeutics has a consensus price target of $11.67, indicating a potential upside of 201.46%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Foghorn Therapeutics beats Boundless Bio on 9 of the 12 factors compared between the two stocks.

How does Boundless Bio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

ALX Oncology has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

ALX Oncology is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 212.93%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

98.0% of ALX Oncology shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Boundless Bio's return on equity of -70.89% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Boundless Bio	N/A	-70.89%	-47.37%

In the previous week, ALX Oncology had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Boundless Bio. ALX Oncology's average media sentiment score of 0.40 beat Boundless Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
ALX Oncology	Neutral
Boundless Bio	Neutral

Summary

ALX Oncology beats Boundless Bio on 8 of the 12 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$65.51M	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	N/A	13.95	274.58	25.69
Price / Sales	N/A	1,357.85	639.38	80.65
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	0.61	15.30	10.44	6.32
Net Income	-$58.20M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-4.26%	-0.22%	0.51%	1.35%
1 Month Performance	-10.00%	-6.06%	-3.38%	-3.68%
1 Year Performance	134.78%	34.37%	16.04%	5.56%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	0.7956 of 5 stars	$2.70 -6.3%	N/A	+155.3%	$65.51M	N/A	N/A	28
BCYC Bicycle Therapeutics	1.8775 of 5 stars	$3.68 +1.1%	$13.86 +276.6%	-47.7%	$254.77M	$72.86M	N/A	288
AKBA Akebia Therapeutics	2.5243 of 5 stars	$0.90 -2.4%	$3.90 +335.5%	-64.9%	$254.33M	$236.20M	N/A	194
CUE Cue Biopharma	3.0616 of 5 stars	$37.84 +10.7%	N/A	-95.1%	$248.23M	$27.47M	N/A	29	News Coverage Analyst Upgrade Gap Down
FHTX Foghorn Therapeutics	1.6065 of 5 stars	$4.20 +0.7%	$11.67 +177.8%	-14.9%	$247.64M	$30.91M	N/A	106	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. BCYC, AKBA, CUE, FHTX, and ALXO

How does Boundless Bio compare to Bicycle Therapeutics?

Summary

How does Boundless Bio compare to Akebia Therapeutics?

Summary

How does Boundless Bio compare to Cue Biopharma?

Summary

How does Boundless Bio compare to Foghorn Therapeutics?

Summary

How does Boundless Bio compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. BCYC, AKBA, CUE, FHTX, and ALXO

How does Boundless Bio compare to Bicycle Therapeutics?

Which has higher earnings and valuation, BCYC or BOLD?

Is BCYC or BOLD more profitable?

Do insiders & institutionals believe in BCYC or BOLD?

Does the media refer more to BCYC or BOLD?

Do analysts rate BCYC or BOLD?

Which has more risk & volatility, BCYC or BOLD?

Summary

How does Boundless Bio compare to Akebia Therapeutics?

Do analysts rate AKBA or BOLD?

Which has preferable valuation and earnings, AKBA or BOLD?

Is AKBA or BOLD more profitable?

Which has more volatility & risk, AKBA or BOLD?

Do institutionals and insiders believe in AKBA or BOLD?

Does the media refer more to AKBA or BOLD?

Summary

How does Boundless Bio compare to Cue Biopharma?

Do insiders and institutionals hold more shares of BOLD or CUE?

Is BOLD or CUE more profitable?

Does the media prefer BOLD or CUE?

Which has more risk & volatility, BOLD or CUE?

Which has better earnings & valuation, BOLD or CUE?

Do analysts recommend BOLD or CUE?

Summary

How does Boundless Bio compare to Foghorn Therapeutics?

Does the media favor BOLD or FHTX?

Do insiders & institutionals believe in BOLD or FHTX?

Which has more risk and volatility, BOLD or FHTX?

Which has higher earnings & valuation, BOLD or FHTX?

Is BOLD or FHTX more profitable?

Do analysts prefer BOLD or FHTX?

Summary

How does Boundless Bio compare to ALX Oncology?

Which has more volatility & risk, ALXO or BOLD?

Which has stronger valuation and earnings, ALXO or BOLD?

Do analysts rate ALXO or BOLD?

Do institutionals and insiders have more ownership in ALXO or BOLD?

Is ALXO or BOLD more profitable?

Does the media refer more to ALXO or BOLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools